Geoffrey Beran Rose net worth and biography

Geoffrey Rose Biography and Net Worth

Insider of Pulmonx

Beran has 20 years of experience driving growth through product strategy, market development, and commercial execution. Prior to Pulmonx, Beran was Global Group Marketing Director at Boston Scientific, where he was responsible for building BSC’s Pulmonary business. He built a new product portfolio and created the market for the first procedure to treat severe asthma. Prior to his role in marketing, Beran was a director of strategy within the R&D and clinical organizations of Boston Scientific. Prior to Boston Scientific, Beran has a decade of management consulting experience for leading healthcare and high-tech companies in Europe and the USA. Beran received a BA from Yale University and an MBA from the MIT Sloan School of Management.

What is Geoffrey Beran Rose's net worth?: The estimated net worth of Geoffrey Beran Rose is at least $2.01 million as of September 3rd, 2024. Mr. Rose owns 295,433 shares of Pulmonx stock worth more than $2,005,990 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Rose may own. Additionally, Mr. Rose receives an annual salary of $632,290.00 as Insider at Pulmonx. Learn More about Geoffrey Beran Rose's net worth.
How old is Geoffrey Beran Rose?: Mr. Rose is currently 50 years old. There are 6 older executives and no younger executives at Pulmonx. The oldest executive at Pulmonx is Mr. David A. Lehman, General Counsel & Secretary, who is 63 years old. Learn More on Geoffrey Beran Rose's age.
What is Geoffrey Beran Rose's salary?: As the Insider of Pulmonx Co., Mr. Rose earns $632,290.00 per year. The highest earning executive at Pulmonx is Mr. David A. Lehman, General Counsel & Secretary, who commands a salary of $651,390.00 per year. Learn More on Geoffrey Beran Rose's salary.
How do I contact Geoffrey Beran Rose?: The corporate mailing address for Mr. Rose and other Pulmonx executives is , , . Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on Geoffrey Beran Rose's contact information.
Has Geoffrey Beran Rose been buying or selling shares of Pulmonx?: Geoffrey Beran Rose has not been actively trading shares of Pulmonx over the course of the past ninety days. Most recently, Geoffrey Beran Rose sold 4,586 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a transaction totalling $30,726.20. Following the completion of the sale, the insider now directly owns 295,433 shares of the company's stock, valued at $1,979,401.10. Learn More on Geoffrey Beran Rose's trading history.
Who are Pulmonx's active insiders?: Pulmonx's insider roster includes Daniel Florin (Director), Glendon French, III (CEO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.
Are insiders buying or selling shares of Pulmonx?: In the last twelve months, Pulmonx insiders bought shares 1 times. They purchased a total of 14,245 shares worth more than $97,435.80. In the last twelve months, insiders at the sold shares 24 times. They sold a total of 138,186 shares worth more than $1,346,575.19. The most recent insider tranaction occured on October, 17th when Director Glendon E French III sold 20,000 shares worth more than $130,400.00. Insiders at Pulmonx own 5.7% of the company. Learn More about insider trades at Pulmonx.
Information on this page was last updated on 10/17/2024.

Geoffrey Beran Rose Insider Trading History at Pulmonx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/3/2024	Sell	4,586	$6.70	$30,726.20	295,433
6/24/2024	Sell	1,184	$6.16	$7,293.44	300,019
6/3/2024	Sell	4,297	$6.97	$29,950.09	301,203
5/22/2024	Sell	1,184	$8.71	$10,312.64	305,500
4/22/2024	Sell	1,184	$7.49	$8,868.16	306,684
3/22/2024	Sell	1,184	$9.36	$11,082.24	307,868
3/1/2024	Sell	3,097	$9.06	$28,058.82	239,952
2/22/2024	Sell	1,184	$14.20	$16,812.80	243,049
1/22/2024	Sell	1,184	$13.13	$15,545.92	244,233
12/22/2023	Sell	1,184	$12.75	$15,096.00	245,417
12/1/2023	Sell	2,868	$10.34	$29,655.12	246,601
11/22/2023	Sell	1,184	$10.60	$12,550.40	249,469
10/23/2023	Sell	1,184	$8.35	$9,886.40	250,653
9/22/2023	Sell	1,184	$10.51	$12,443.84	251,837
9/1/2023	Sell	2,843	$10.01	$28,458.43	253,021
8/23/2023	Sell	1,184	$10.54	$12,479.36	255,864
6/1/2023	Sell	2,845	$11.48	$32,660.60	257,048
3/1/2023	Sell	1,206	$11.03	$13,302.18	180,993
12/1/2022	Sell	1,055	$5.93	$6,256.15	181,037
6/1/2022	Sell	1,011	$18.05	$18,248.55	183,118
12/15/2021	Sell	22,000	$30.55	$672,100.00
12/1/2021	Sell	355	$32.73	$11,619.15
11/15/2021	Sell	7,000	$39.94	$279,580.00
10/15/2021	Sell	7,000	$39.44	$276,080.00
9/15/2021	Sell	7,000	$38.12	$266,840.00	159,814
9/1/2021	Sell	355	$40.09	$14,231.95
8/16/2021	Sell	7,000	$36.71	$256,970.00
7/15/2021	Sell	7,000	$38.73	$271,110.00	180,127
5/24/2021	Sell	4,797	$40.88	$196,101.36
5/10/2021	Sell	4,797	$40.70	$195,237.90	117,692
4/19/2021	Sell	4,797	$43.24	$207,422.28	121,470
4/5/2021	Sell	4,797	$47.64	$228,529.08	109,330

Geoffrey Beran Rose Buying and Selling Activity at Pulmonx

Pulmonx Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Today's Range

Now: $6.79

$6.25

$6.84

50 Day Range

MA: $7.07

$6.00

$8.58

2 Week Range

Now: $6.79

$5.46

$14.84

Volume

294,058 shs

Average Volume

233,713 shs

Market Capitalization

$268.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

Geoffrey Rose Biography and Net Worth

What is Geoffrey Beran Rose's net worth?

How old is Geoffrey Beran Rose?

What is Geoffrey Beran Rose's salary?

How do I contact Geoffrey Beran Rose?

Has Geoffrey Beran Rose been buying or selling shares of Pulmonx?

Who are Pulmonx's active insiders?

Are insiders buying or selling shares of Pulmonx?